eFFECTOR Therapeutics, Inc.

Alumis, Inc. planned to raise between $282.4m and $317.7m in the last biopharmaceutical initial public offering in the US during the first half of 2024, but instead grossed $250m on 27 June from the

Special purpose acquisition corporations did not have a very successful run in the last SPAC wave to hit the life science sector, but a new round of the vehicles that provide companies an alternative

eFFECTOR Therapeutics, Inc. is placing its bets on a breast cancer drug candidate following the failure in a mid-stage trial of tomivosertib for non-small cell lung cancer (NSCLC), an indication wher

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning